Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ENROLLING BY INVITATION
NCT06851403
The Effectiveness and Safety of Dupilumab in Children with Asthma in China: a Real-world Study
Sponsor: Guangzhou Institute of Respiratory Disease
View on ClinicalTrials.gov
Summary
Observe the changes of type II inflammation markers, lung function, and symptom scores in asthmatic patients aged 6 to 14 during the use of dupilumab to analyze its efficacy.
Official title: The Effectiveness and Safety of Dupilumab in Children with Severe Asthma in China: a Real-world Study
Key Details
Gender
All
Age Range
4 Years - 16 Years
Study Type
OBSERVATIONAL
Enrollment
213
Start Date
2022-01-30
Completion Date
2025-12-30
Last Updated
2025-02-28
Healthy Volunteers
No
Conditions
Interventions
DRUG
Dupilumab
initial injection of 600 mg, followed by maintenance injections of 300 mg every four weeks
Locations (1)
Guangzhou institute of respiratory disease
Guangzhou, Guangdong, China